Sumary of Biogen’s Alzheimer’s drug could cost Medicare billions of dollars a year, report finds:
- The biotech company said it is charging $56,000 for an annual course of the new treatment, higher than the $10,000 to $25,000 price some Wall Street analysts were expecting..
- Aduhelm will be covered under Medicare Part B, KFF said, which generally covers FDA-approved physician-administered medications..
- “If 1 million Medicare beneficiaries receive Aduhelm, which may even be on the low end of Biogen’s expectations, spending on Aduhelm alone would exceed $57 billion dollars in a single year – far surpassing spending on all other Part B-covered drugs combined,”.
- On a call with investors Tuesday morning, Evercore ISI analyst Umer Raffat congratulated the Massachusetts-based company on the drug’s U.S….